Christian P. Mclean

Array ( [id] => 20121641 [patent_doc_number] => 20250236672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-24 [patent_title] => ANTIGEN BINDING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 19/172374 [patent_app_country] => US [patent_app_date] => 2025-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43998 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19172374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19996708 [patent_doc_number] => 20250134930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => REGULATION OF CELLS AND ORGANISMS [patent_app_type] => utility [patent_app_number] => 18/926059 [patent_app_country] => US [patent_app_date] => 2024-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18926059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862320 [patent_doc_number] => 20250101106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => ANTIGEN BINDING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/919069 [patent_app_country] => US [patent_app_date] => 2024-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18919069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743982 [patent_doc_number] => 20250032547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 18/917836 [patent_app_country] => US [patent_app_date] => 2024-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18917836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743982 [patent_doc_number] => 20250032547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 18/917836 [patent_app_country] => US [patent_app_date] => 2024-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18917836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743982 [patent_doc_number] => 20250032547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 18/917836 [patent_app_country] => US [patent_app_date] => 2024-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18917836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19876956 [patent_doc_number] => 20250109213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/915927 [patent_app_country] => US [patent_app_date] => 2024-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 192 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18915927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19876956 [patent_doc_number] => 20250109213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/915927 [patent_app_country] => US [patent_app_date] => 2024-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 192 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18915927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691333 [patent_doc_number] => 20250009878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/887598 [patent_app_country] => US [patent_app_date] => 2024-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18887598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691333 [patent_doc_number] => 20250009878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/887598 [patent_app_country] => US [patent_app_date] => 2024-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18887598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922997 [patent_doc_number] => 20240026001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => USE OF ANTI-IL-27 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/201620 [patent_app_country] => US [patent_app_date] => 2023-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18201620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739666 [patent_doc_number] => 20230348630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => ANTIBODIES BINDING BCMA AND CD3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/307299 [patent_app_country] => US [patent_app_date] => 2023-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18307299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612378 [patent_doc_number] => 20230279110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => ANTI-CD47 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/189998 [patent_app_country] => US [patent_app_date] => 2023-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 786 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18189998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565739 [patent_doc_number] => 20230256066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/119103 [patent_app_country] => US [patent_app_date] => 2023-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18119103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18816053 [patent_doc_number] => 20230390392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/179201 [patent_app_country] => US [patent_app_date] => 2023-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18179201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844853 [patent_doc_number] => 20230407257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => TRANSFORMED NATURAL KILLER CELL [patent_app_type] => utility [patent_app_number] => 18/177023 [patent_app_country] => US [patent_app_date] => 2023-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18177023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879174 [patent_doc_number] => 20240002543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/173995 [patent_app_country] => US [patent_app_date] => 2023-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 152461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18173995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879174 [patent_doc_number] => 20240002543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/173995 [patent_app_country] => US [patent_app_date] => 2023-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 152461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18173995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612372 [patent_doc_number] => 20230279104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => TM4SF5-TARGETING HUMANIZED ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/154597 [patent_app_country] => US [patent_app_date] => 2023-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709217 [patent_doc_number] => 20230331829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => BINDING MOLECULE ABLE TO NEUTRALIZE PROX1 PROTEIN [patent_app_type] => utility [patent_app_number] => 18/089393 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18089393 [rel_patent_id] =>[rel_patent_doc_number] =>)